Long-term Multiple Center Experience in Treating Plaque Psoriasis with Halobetasol Propionate 0.01% and Tazarotene 0.045% Lotion

Published: 3 January 2023| Version 1 | DOI: 10.17632/kh9htwwkt5.1
Contributor:
Abe Mula

Description

Clinical trial data regarding the efficacy of halobetasol propionate 0.01% and tazarotene 0.045% lotion (HP/TAZ), a super-potent corticosteroid and retinoid fixed combination topical medication, has been promising. Despite this, real-world experience of HP/TAZ in a community setting is limited.

Files

Categories

Dermatology

Licence